place

North Chicago station

Former Chicago and North Western Railway stationsIllinois railway station stubsMetra stations in IllinoisNorth Chicago, IllinoisPages with no open date in Infobox station
Railway stations in Lake County, IllinoisUnion Pacific North Line
North Chicago Station
North Chicago Station

North Chicago is one of two commuter rail stations on Metra's Union Pacific North Line located in North Chicago, Illinois. North Chicago is located at 1633 Lakeside Avenue, 33.7 miles (54.2 km) away from Ogilvie Transportation Center, the southern terminus of the Union Pacific North Line. In Metra's zone-based fare system, North Chicago is located in zone G. As of 2018, North Chicago is the 168th busiest of Metra's 236 non-downtown stations, with an average of 170 weekday boardings.Prior to the construction of the current facility, North Chicago was situated 1⁄2 mile (0.80 km) south of the present location, near Nimitz Avenue. The station consists of two side platforms which serve two tracks. An unstaffed station house is on the inbound (east) platform. Parking is available at North Chicago in a city-owned lot on the west side of the tracks. North Chicago is little more than a shelter, though it is served regularly. As of April 25, 2022, North Chicago is served by 23 trains in each direction on weekdays, by 11 trains in each direction on Saturdays, and by eight trains in each direction on Sundays.

Excerpt from the Wikipedia article North Chicago station (License: CC BY-SA 3.0, Authors, Images).

North Chicago station
Lakeside Avenue,

Geographical coordinates (GPS) Address Nearby Places
placeShow on map

Wikipedia: North Chicago stationContinue reading on Wikipedia

Geographical coordinates (GPS)

Latitude Longitude
N 42.3288 ° E -87.837 °
placeShow on map

Address

North Chicago

Lakeside Avenue 1633
60064
Illinois, United States
mapOpen on Google Maps

North Chicago Station
North Chicago Station
Share experience

Nearby Places

AbbVie
AbbVie

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira (adalimumab) ($14 billion in 2023 revenues, 27 percent of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis. It developed Skyrizi ($7.8 billion in 2023 revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases. Its other major products include Botox ($5.7 billion in 2023 revenues), Imbruvica to treat cancer ($3.6 billion in 2023 revenues), Rinvoq to treat arthritis ($4 billion in 2023 revenues), Venclexta to treat leukemia and lymphoma ($2.3 billion in 2023 revenues), Vraylar to treat schizophrenia and bipolar disorder ($2.7 billion in 2023 revenues), and Mavyret to treat Hepatitis C ($1.4 billion in 2023 revenues).: 39–40  The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.: 34  In 2023, Humira began facing competition from a biosimilar developed by Amgen. The company is also developing a drug for Parkinson's disease that could be a blockbuster drug in 2027 and is awaiting approval from the Food and Drug Administration for epcoritamab, a blood-cancer therapy under development in partnership with Genmab. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'.